Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Alnylam Pharmaceuticals’s reported figures.
The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026. Open the filing →
- Filed
- Jul 30, 2026, 8:11 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001178670-26-000062
FAQ
- What is Alnylam Pharmaceuticals's EBIT?
- Alnylam Pharmaceuticals (ALNY) reported EBIT of $231.44M in Q2 2026.
- How has Alnylam Pharmaceuticals's EBIT changed year-over-year?
- Alnylam Pharmaceuticals's EBIT increased by 1528.7% year-over-year, from -$16.2M to $231.44M.
- What is the long-term trend for Alnylam Pharmaceuticals's EBIT?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's EBIT has grown at a -8.3% compound annual growth rate (CAGR), from -$708.65M to $501.58M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Alnylam Pharmaceuticals's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude